Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients - Full Text View

Purpose

This is an open label, single center, randomized, active comparator controlled study, comparing the effects of vitamin D replacement using oral ergocalciferol versus paricalcitol on parathyroid hormone (PTH) levels in patients with stage 3 and 4 CKD and vitamin D deficiency or insufficiency. The purpose of this study is to determine which of these two approaches is more successful.

Condition	Intervention	Phase
Secondary Hyperparathyroidism Chronic Kidney Disease	Drug: Paricalcitol Drug: Ergocalciferol	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial

Resource links provided by NLM:

MedlinePlus related topics: Kidney Diseases Vitamin D Vitamin D Deficiency

Drug Information available for: Ergocalciferol Vitamin D Paricalcitol

U.S. FDA Resources

Further study details as provided by Salem Veterans Affairs Medical Center:

Primary Outcome Measures:

To achieve 2 consecutive iPTH measurements with 30% or greater decrease from baseline [ Time Frame: 2 years ]

Secondary Outcome Measures:

To achieve 25OHD level above 30 ng/ml and change cardiovascular markers [ Time Frame: 2 years ]


Estimated Enrollment:	80
Study Start Date:	July 2009
Study Completion Date:	January 2011
Primary Completion Date:	January 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Paricalcitol Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.	Drug: Paricalcitol Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml; Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks. Drug: Ergocalciferol If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.
Active Comparator: Ergocalciferol Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.	Drug: Paricalcitol Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml; Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks. Drug: Ergocalciferol If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.

Arms

Assigned Interventions

Active Comparator: Paricalcitol

Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.

Drug: Paricalcitol

Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;
Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.

Drug: Ergocalciferol

If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.
If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.
If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.

Active Comparator: Ergocalciferol

Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.

Drug: Paricalcitol

Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;
Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.

Drug: Ergocalciferol

If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.
If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.
If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.

Detailed Description:

This study will enroll chronic kidney disease patients, stage 3 and 4, who have low serum vitamin D levels as defined by K DOQI Guidelines. Patients will be randomized to receive oral daily ergocalciferol or paricalcitol. A total of 80 patients will be enrolled, 40 in the cholecalciferol group and 40 in the paricalcitol group. Outcomes will be assessed as proportion of patients achieving pre-defined changes from baseline and as absolute changes from baseline values. Baseline values will be determined from averaging two consecutive measurements of the variables of interest prior to randomization.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female chronic kidney disease patients at least 18 years of age.
Patients should be able and willing to provide written informed consent and HIPAA Authorization.
Chronic kidney disease stage 3 or 4.
Plasma intactPTH level above 75pg/ml.
Serum 25 OHD level below 30ng/ml.
Negative pregnancy test unless 2 years postmenopausal or with a documented tubal ligation or total hysterectomy.
Patients need to be off of any Vitamin analogues or preparations for 4 weeks prior to screening.

Exclusion Criteria:

Women who are breast feeding, pregnant, capable of becoming pregnant, and not participating in an acceptable form of birth control.
Patients currently participating in a clinical trial with another investigational drug or device or who have receive an investigational drug or device within 30 days of enrollment in this study.
Major surgery within one month prior to enrollment or planned surgery while patient is in study (other than dialysis vascular access surgery).
Patients who have had a malignancy unless they have received curative treatment and have been disease free for 2 years.
Patients with a medical status that the PI decides would preclude participation.
Patients on hemodialysis or peritoneal dialysis.
Patients with a functional renal transplant.
Patients with allergies to study drugs.
Patients with acute renal failure with the past 12 weeks.
Patients with clinically significant gastrointestinal or liver disease.
Patients with active granulomatous disease.
Patients with urine calcium:creatinine ratio of more than 0.2.
Patients who received vitamin D analogs, calcimimetics, or biphosphonates within 4 weeks before screening. Treatment with any one of these medicines during the study is not permitted.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00958451

Locations


United States, Virginia
VA Medical Center
Salem, Virginia, United States, 24153

Sponsors and Collaborators

Salem Veterans Affairs Medical Center

Abbott

Investigators


Principal Investigator:	Csaba P. Kovesdy, M.D.	Salem VAMC

More Information


Responsible Party:	Csaba P. Kovesdy, M.D., Salem VAMC
ClinicalTrials.gov Identifier:	NCT00958451 History of Changes
Other Study ID Numbers:	CK0023
Study First Received:	August 11, 2009
Last Updated:	March 23, 2011

Keywords provided by Salem Veterans Affairs Medical Center:


Calcium Vitamin D deficiency Chronic Kidney disease

Additional relevant MeSH terms:


Kidney Diseases Neoplasm Metastasis Renal Insufficiency, Chronic Hyperparathyroidism Vitamin D Deficiency Hyperparathyroidism, Secondary Urologic Diseases Neoplastic Processes Neoplasms Pathologic Processes Renal Insufficiency Parathyroid Diseases	Endocrine System Diseases Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders Vitamins Vitamin D Ergocalciferols Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents

ClinicalTrials.gov processed this record on September 18, 2017